These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 8291866

  • 1. Superficial urinary bladder cancer. Results from the Finnbladder studies and a review on instillation treatments.
    Jauhiainen K, Rintala E.
    Ann Chir Gynaecol Suppl; 1993; 206():31-8. PubMed ID: 8291866
    [Abstract] [Full Text] [Related]

  • 2. Instillation therapy in superficial urinary bladder cancer. Finnbladder Group.
    Jauhiainen KE, Alfthan OS.
    Scand J Urol Nephrol Suppl; 1991; 138():179-85. PubMed ID: 1785001
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of principles in intravesical chemo- and immunotherapy for superficial bladder cancer.
    Jauhiainen K, Rintala E, Kaasinen E, Ruutu M, Alfthan O.
    Arch Esp Urol; 1990; 43 Suppl 2():159-64. PubMed ID: 2129004
    [Abstract] [Full Text] [Related]

  • 4. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
    Yumura Y, Oogo Y, Takase K, Hamano A, Yamashita Y, Noguchi S, Satomi Y.
    Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
    [Abstract] [Full Text] [Related]

  • 5. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
    Fujimoto K, Chihara Y, Kondo H, Hirao Y.
    Hinyokika Kiyo; 2006 Jun; 52(6):433-8. PubMed ID: 16848356
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. High-risk superficial bladder cancer: intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder.
    Pham HT, Soloway MS.
    Semin Urol Oncol; 1997 Aug; 15(3):147-53. PubMed ID: 9394909
    [Abstract] [Full Text] [Related]

  • 9. [Treatment of stage Ta,T1 and Tis bladder tumors using Calmette-Guérin bacillus vaccine].
    Bretheau D, Lechevallier E, Rossi D, Albert P, de Fromont M, Coulange C.
    Prog Urol; 1993 Aug; 3(4):608-17. PubMed ID: 8401621
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Bacillus Calmette-Guérin immunotherapy. Techniques and results.
    Brosman SA.
    Urol Clin North Am; 1992 Aug; 19(3):557-64. PubMed ID: 1636239
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Intravesical adjuvant chemotherapy for superficial bladder cancer -- results of a survey in Saxony].
    Steinbach F, Schuster F.
    Aktuelle Urol; 2005 Aug; 36(4):337-41. PubMed ID: 16110407
    [Abstract] [Full Text] [Related]

  • 14. Management of superficial transitional cell carcinoma of the bladder.
    Fleischmann J, Goldberg G.
    Semin Urol; 1993 Nov; 11(4):193-204. PubMed ID: 8290825
    [Abstract] [Full Text] [Related]

  • 15. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
    Herr HW.
    J Urol; 2005 Dec; 174(6):2134-7. PubMed ID: 16280743
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder.
    van der Heijden AG, Kiemeney LA, Gofrit ON, Nativ O, Sidi A, Leib Z, Colombo R, Naspro R, Pavone M, Baniel J, Hasner F, Witjes JA.
    Eur Urol; 2004 Jul; 46(1):65-71; discussion 71-2. PubMed ID: 15183549
    [Abstract] [Full Text] [Related]

  • 18. Recurrent or aggressive bladder cancer. Indications for adjuvant intravesical therapy.
    Badalament RA, Ortolano V, Burgers JK.
    Urol Clin North Am; 1992 Aug; 19(3):485-98. PubMed ID: 1636233
    [Abstract] [Full Text] [Related]

  • 19. Marker tumour responses to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group (EORTC 30897).
    Van der Meijden AP, Hall RR, Macaluso MP, Pawinsky A, Sylvester R, Van Glabbeke M.
    Eur Urol; 1996 Aug; 29(2):199-203. PubMed ID: 8647147
    [Abstract] [Full Text] [Related]

  • 20. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED.
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.